SFM
PTCT icon

Sphera Funds Management’s PTC Therapeutics PTCT Stock Holding History

Sphera Funds Management’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-1,600
Closed -$4.27M – 131
2015
Q3 		$4.27M Buy
1,600
+1,000
+167% +$42.8K 0.55% 34
2015
Q2 		$2.89M Hold
600
– – 0.28% 92
2015
Q1 		$3.65M Buy
+600
New +$36.6K 0.38% 64

Other funds holding PTCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Sphera Funds Management's PTCT Position: Q4 2024 in Review

Sphera Funds Management sold out of PTC Therapeutics (PTCT) in Q4 2024, closing a stake of 118,345 shares — an estimated $4.39M sold.

Sphera Funds Management first reported a position in PTCT in Q4 2013 and held it in 22 quarters. The position peaked at $11.9M in Q4 2018. 240 funds tracked by Wall St. Rank hold PTCT as of Q4 2024.

  • Sphera Funds Management reported no remaining PTC Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Sphera Funds Management sold 118,345 PTC Therapeutics shares in Q4 2024, an estimated $4.39M.
  • Sphera Funds Management first reported a position in PTC Therapeutics in Q4 2013 and held it in 22 quarters.
  • Sphera Funds Management's PTC Therapeutics position peaked at $11.9M in Q4 2018.
  • 240 funds tracked by Wall St. Rank held PTC Therapeutics as of Q4 2024.

Based on Sphera Funds Management's 13F filing for Q4 2024, filed 14 Feb 2025.